Table 2 Dosages and duration of Mirtazapine (MTZ) treatment on patients
From: Protective role of mirtazapine in adult female Mecp2+/− mice and patients with Rett syndrome
MTZ treatment in RTT | ||||
|---|---|---|---|---|
Patient | Daily dose (mg/day) | Per kg dose (mg kg bw/day) | Treatment duration (years) | Tolerance |
No. 1 | 7.5 | 0.170 | 2 | T |
No. 2 | 15 | 0.375 | 2 | T |
No. 3 | 7.5 | 1.071 | 2 | T |
No. 4 | 30 | 0.428 | 5 | T |
No. 5 | 30 | 0.806 | 2 | T |
No. 6 | 15 | 0.395 | 1 | T |
No. 7 | 15 | 0.288 | 2 | NT |
No. 8 | 22.5 | 0.625 | 3 | T |
No. 9 | 7.5 | 0.306 | 1 | T |
No. 10 | 15 | 0.288 | 2 | T |
No. 11 | 15 | 0.441 | 0.08 | NT |
No. 12 | 3.75 | 0.122 | 1.4 | T |
No. 13 | 3.75 | 0.170 | 1 | T |
No. 14 | 7.5 | 0.250 | 1.2 | T |
No. 15 | 7.5 | 0.187 | 0.08 | NT |
No. 16 | 15 | 0.273 | 0.5 | NT |
No. 17 | 7.5 | 1.970 | 1.4 | T |
No. 18 | 3.75 | 0.288 | 1 | T |
No. 19 | 7.5 | 0.115 | 2 | T |
No. 20 | 15 | 0.300 | 1.7 | T |
No. 21 | 7.5 | 0.263 | 1.1 | T |
No. 22 | 7.5 | 0.250 | 1.4 | T |
No. 23 | 7.5 | 0.166 | 1.2 | T |
No. 24 | 15 | 0.250 | 1.5 | T |
No. 25 | 15 | 0.220 | 1.1 | T |
No. 26 | 15 | 0.211 | 1 | T |
No. 27 | 7.5 | 0.227 | 1.2 | T |
No. 28 | 15 | 0.286 | 1 | T |
No. 29 | 15 | 0.214 | 2.4 | T |
No. 30 | 15 | 0.300 | 2.1 | T |
No. 31 | 15 | 0.329 | 5 | T |
No. 32 | 7.5 | 0.205 | 2.3 | T |
No. 33 | 7.5 | 0.246 | 2 | T |
No. 34 | 7.5 | 0.117 | 1.1 | T |
No. 35 | 7.5 | 0.227 | 1.5 | T |
No. 36 | 3.75 | 0.174 | 1 | T |
No. 37 | 7.5 | 0.246 | 2.2 | T |
No. 38 | 7.5 | 0.258 | 1.3 | T |
No. 39 | 7.5 | 0.246 | 2.2 | T |
No. 40 | 3.75 | 0.134 | 1.2 | T |